International Journal of Hematological Disorders
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: http://www.sciepub.com/journal/ijhd Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
International Journal of Hematological Disorders. 2015, 2(2), 47-53
DOI: 10.12691/ijhd-2-2-5
Open AccessArticle

A Study of the Natural Coagulating Inhibitors Polymorphism in Iranian Patients with the Vine Thrombosis

Mohsen Hamidpour1, , Hosien Jahangir1, Mortaza Safi2, Gholamreza Toogeh3, Mehdi Allahbakhshian1, Rafie Hamidpour4 and Ali Akbar Khadem mabodi5

1Department of Hematology & Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Cardio Vascular Research center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences

3Thrombosis Disease Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran-Iran

4Department of Herbal medicine, Pars Biosciences Research center, Kansas, USA

5Department of Biostatistical, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Pub. Date: January 06, 2016

Cite this paper:
Mohsen Hamidpour, Hosien Jahangir, Mortaza Safi, Gholamreza Toogeh, Mehdi Allahbakhshian, Rafie Hamidpour and Ali Akbar Khadem mabodi. A Study of the Natural Coagulating Inhibitors Polymorphism in Iranian Patients with the Vine Thrombosis. International Journal of Hematological Disorders. 2015; 2(2):47-53. doi: 10.12691/ijhd-2-2-5

Abstract

Introduction: Anti thrombin III (AT-III), protein C (PC), protein S (PS) are named the natural coagulation inhibitors, quantitative and qualitative defects of these inhibitor proteins caused recurrent veins thrombosis. Despite there are many clinical and technical assays for improving diagnosis of this disease, but diagnosis and classification of this disease facing with some challenges. The diagnosis polymorphism and mutation of PC, PS, and Anti-III, recognizing the homozygote and heterozygote form in people who have any patient with vein thrombosis in their family. Materials & Methods: 42 patients with vascular thrombosis, who visited cardiovascular and thromboses clinic of Immam khomaini and Shahid Modarres General Hospitals have been studied in this research. After performing coagulation test and determining the activity of anti coagulation proteins (PC, PS, Anti-III), The DNA of patients samples were extracted and reproduce by PCR. Pieces of DNA upon reproduction sent to Biosciences Co in UK to determining its sequence. DNA sequences were comprised with wild type of proteins genome. Results: The activities of PS in 63.5%, PC in 29.2 and AT-III in 7.3% patients were reduced. There was a statistical relation between reducing plasma activity of PC and PS of patients and their familial thrombosis (P< 0.05). Results obtained from Chromas software showed that there are remarkable polymorphisms in some patients who are suffered from abnormal of related proteins. Discussion & Conclusion: Although, many studies are performed in development countries for recognizing this disease, there is not a lot of study which carried out in Iran about this issue. Therefore, it is required to perform more molecular tests on natural coagulation inhibitors and other effective proteins on creation of vascular thrombosis.

Keywords:
vascular thrombosis polymorphism natural coagulation inhibitors

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A.The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologic. 1997; 82(4):423-428.
 
[2]  Virchow R. Phlogose und Thrombose im Gefässytem. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin Frankfurt: Staatsdruckerei. 1856.
 
[3]  Heit JA, O’Fallon WM, Pett erson TM, Lohse CM, Silverstein MD, Mohr DN, Melton III L Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162: 1245-1248.
 
[4]  White R. The epidemiology of venous thromboembolism. Circulation 2003; 107:14-18.
 
[5]  Geerts WH, Pineo GF, Heit JA. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004; 126(3Sup):38-40.
 
[6]  Van Sluis GL, Sohne M, El Kheir DY, Tanck MW, Gerdes VE, Büller HR. Family history and inherited thrombophilia. 2006; 4:2182-2187.
 
[7]  Roosendaal FR. Venous thrombosis: the role of environment, and behavior. Lecture in Hematology (Am Soc Hematol Educ Program). 2005; 1-12.
 
[8]  Bertina RM. Genetic approach to thrombophilia. Thromb Haemost. 2001; 86:92-103.
 
[9]  Poort SR, Roosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’ untranslated region of the prothrombin is associated with elevated plasma prothrombin level and an increase in venous thrombosis. Blood. 1996; 88:3698-3703.
 
[10]  Heit JA, Phelps MA, Ward SA, Slusser JP, Pett erson TM, De Andrade M. Familial segregation of venous thromboembolism. J Thromb Haemost. 2004; 2:731-736.
 
[11]  Roosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watz ke HH,Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998; 79:706-708.
 
[12]  Castoldi E and Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010; 8:445-53.
 
[13]  Franco RF and Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genetic 2001; 109:369-84.
 
[14]  Bounameaux H and Roosendaal FR. Venous thromboembolism: Why does ethnicity matter? Circulation. 2011; 123:2189-91.
 
[15]  Nossent AY, Eikenboom JC, Bertina RM. Plasma coagulation factor levels in venous thrombosis. Semin Hematol. 2007; 44:77-84.
 
[16]  Van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003; 1:2677-2678.
 
[17]  Bovill EG, Hasstedt SJ, Leppert MF, Long GL. Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost. 1999; 82:662-666.
 
[18]  Tienan Zhu, Qiulan Ding, Xia Bai, Xiaoyan Wang, Florentia Kaguelidou Corinne Alberti, Xuqian Wei,Baolai Hua, Renchi Yang, Xuefeng Wang, Zhaoyue Wang,Changgeng Ruan, Nicole Schlegel, and Yongqiang Zhao. Normal ranges and genetic underlying variants of antithrombin, protein C and proteinS in the genral Chinese population. Haematologica 2011.
 
[19]  Donaldson GA, Williams C, Scannell JG. A reappraisal of the application of the Trendelenburg operation to massive fatal embolism: report of a successful pulmonary-artery thrombectomy using acardiopulmonary bypass. N Engl J Med 1963;268: 171-174.
 
[20]  Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734-742.
 
[21]  SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162:1144-1148.
 
[22]  Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haem 2005; 3:1554-1560.
 
[23]  Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5:692-699.
 
[24]  E. Nizankowska-Mogilnicka, L. Adamek, P. Grzanka, T.B. Domagala, M. Sanak, M. Krzanowski and A. Szczeklik. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur. Respiratory .journal.2003; 1:25-30.
 
[25]  L, Minuk, A, Lazo-Langner, J, Kovacs٬ M, Robbins, B, Morrow and M, Kovacs. Normal level of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated. Thrombosis Journal 2010, 8:10.
 
[26]  Ahmadinezhad M., Rajabi A., Bashash D., Zoualfaghari S, Tabatabaei SMR., Atarodi K., Seyadmortaz L., Balouch S., Amini Kafiabad S., Abouaghasemi H. Hereditary thrombophilic deficiencies in Iranian patients patients with venous thromboembolis referred to special coagulantion laboratory of IBTO. Khoon. 2010, 1,7-15.
 
[27]  Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y. Protein S and protein C mutations in Japanese deep vein thrombosis patients. Clin Biochem 2005; 38:908-15.
 
[28]  Liu HW, Kong YL, Bourke C, Lam CK, Lie AK, Wei D. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994; 71:416-9.
 
[29]  Gandrille S, Borgel D, Sala N, Espinosa-Parrilla Y, Simmonds R, Rezende S, Lind B, Mannhalter C, Pabinger I, Reitsma PH, Formstone C, Cooper DN, Saito H, Suzuki K, Bernardi F, Aiach M. Protein S deficiency: a database of mutations—summary of the first update. Thromb Haemost. 2000; 84(5):918.
 
[30]  Yin T, Takeshita S, Sato Y, Sakata T, Shin Y, Honda S, Kawasaki T, Tsuji H, Kojima T, Madoiwa S, Sakata Y, Murata M, Ikeda Y, Miyata T. A large deletion of the PROS1 in a deep vein thrombosis patient with protein S deficiency. Thromb Haemost. 2007; 98(4):783-789.
 
[31]  Hamasaki N, Kuma H, Tsuda H. Activated protein C anticoagulant system dysfunction and thrombophilia in Asia. Ann Lab Med 2013 33(1):8-13.
 
[32]  Tong Yin, Toshiyuki Miyata. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in Northeast Asians. J Thromb Thrombolysis. 2014; 37:56-65.
 
[33]  Naotaka Hamasaki, Hiroyuki Kuma, Hiroko Tsuda. Activated Protein C Anticoagulant system dysfunction and thrombophilia in Asia Ann Lab Med 2013;33:8-13.
 
[34]  Tang L, Guo T, Yang R, Mei H, Wang H, Lu X, Yu J, Wang Q, Hu Y. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS ONE. 2012; 7(4):e35773.
 
[35]  Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA .2008; 299(11):1306-14.
 
[36]  Miyata T, Hamasaki N, Wada H, Kojima T. More on: racial differences in venous thromboembolism. J Thromb Haemost. 2012; 10(2):319-320.